<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hematopoietic cell transplantation is the only curative therapy for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, treatment-related toxicity and, in patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>]; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>]) or transformation to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (tAML), posttransplantation relapse continue to be prevalent </plain></SENT>
<SENT sid="2" pm="."><plain>Induction chemotherapy (IC) has been used in an attempt to decrease the risk of posttransplantation relapse, but the benefit for posttransplantation long-term survival is uncertain </plain></SENT>
<SENT sid="3" pm="."><plain>We reviewed results in 125 patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and tAML who received transplants from HLA-identical related or unrelated donors after preparation with myeloablative conditioning regimens </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-three patients (3 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 6 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, and 24 with tAML) received IC before transplantation, and 92 patients (62 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 22 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, and 8 with tAML) did not </plain></SENT>
<SENT sid="5" pm="."><plain>Seventy-six patients were conditioned with oral <z:chebi fb="0" ids="28901">busulfan</z:chebi> 16 mg/kg, which was adjusted to achieve steady-state plasma concentrations of 800 to 900 ng/mL, plus <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 2 x 60 mg/kg, and 49 patients received <z:chebi fb="0" ids="28901">busulfan</z:chebi> 7 mg/kg (without dose adjustment) and total body irradiation 6 x 200 cGy given over 3 days </plain></SENT>
<SENT sid="6" pm="."><plain>There was no evidence of a benefit in posttransplantation outcome associated with prior IC, either for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> or those with tAML, with either conditioning regimen </plain></SENT>
<SENT sid="7" pm="."><plain>There was a correlation of the severity of pretransplantation flow cytometric aberrancies on marrow cells and posttransplantation relapse </plain></SENT>
<SENT sid="8" pm="."><plain>Further studies that randomize patients to IC versus no IC need to appropriately address the possible beneficial effect of IC </plain></SENT>
</text></document>